Oseroff Carla, Peters Bjoern, Pasquetto Valerie, Moutaftsi Magdalini, Sidney John, Panchanathan Vijay, Tscharke David C, Maillere Bernard, Grey Howard, Sette Alessandro
Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA.
J Immunol. 2008 Jun 1;180(11):7193-202. doi: 10.4049/jimmunol.180.11.7193.
Understanding immunity to vaccinia virus (VACV) is important for the development of safer vaccines for smallpox- and poxvirus-vectored recombinant vaccines. VACV is also emerging as an outstanding model for studying CD8(+) T cell immunodominance because of the large number of CD8(+) T cell epitopes known for this virus in both mice and humans. In this study, we characterize the CD8(+) T cell response in vaccinated BALB/c mice by a genome-wide mapping approach. Responses to each of 54 newly identified H-2(d)-restricted T cell epitopes could be detected after i.p. and dermal vaccination routes. Analysis of these new epitopes in the context of those already known for VACV in mice and humans revealed two important findings. First, CD8(+) T cell epitopes are not randomly distributed across the VACV proteome, with some proteins being poorly or nonimmunogenic, while others are immunoprevalent, being frequently recognized across diverse MHC haplotypes. Second, some proteins constituted the major targets of the immune response by a specific haplotype as they recruited the majority of the specific CD8(+) T cells but these proteins did not correspond to the immunoprevalent Ags. Thus, we found a dissociation between immunoprevalence and immunodominance, implying that different sets of rules govern these two phenomena. Together, these findings have clear implications for the design of CD8(+) T cell subunit vaccines and in particular raise the exciting prospect of being able to choose subunits without reference to MHC restriction.
了解对痘苗病毒(VACV)的免疫对于开发更安全的天花疫苗和痘病毒载体重组疫苗至关重要。由于在小鼠和人类中已知该病毒有大量的CD8(+) T细胞表位,VACV也正在成为研究CD8(+) T细胞免疫显性的杰出模型。在本研究中,我们通过全基因组定位方法对接种疫苗的BALB/c小鼠中的CD8(+) T细胞反应进行了表征。经腹腔注射和皮肤接种途径后,可检测到对54个新鉴定的H-2(d)限制性T细胞表位中每一个的反应。在小鼠和人类中已针对VACV所知的那些表位的背景下对这些新表位进行分析,揭示了两个重要发现。首先,CD8(+) T细胞表位并非随机分布在VACV蛋白质组中,一些蛋白质免疫原性差或无免疫原性,而其他蛋白质则具有免疫普遍性,在不同的MHC单倍型中经常被识别。其次,一些蛋白质作为特定单倍型免疫反应的主要靶点,因为它们募集了大多数特定的CD8(+) T细胞,但这些蛋白质并不对应于免疫普遍的抗原。因此,我们发现免疫普遍性和免疫显性之间存在分离,这意味着不同的规则集支配这两种现象。这些发现共同对CD8(+) T细胞亚单位疫苗的设计具有明确的意义,特别是提出了能够在不参考MHC限制的情况下选择亚单位的令人兴奋的前景。